Position in AMGN
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$956,358
+$496,491 QoQ
Shares Held
2,641
+102.1% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#1,724
of 3,140 holders
Holding Since
Mar 2020
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AMGN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $7,172,969 across 8 Drug Manufacturers - General names. AMGN ranks #4 (13.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BMY |
Bristol Myers Squibb Co
|
28,898 | $1,665,102 | |
| 2 | LLY |
ELI LILLY & Co
|
1,075 | $1,289,387 | |
| 3 | GILD |
Gilead Sciences, Inc.
|
9,877 | $1,247,860 | |
| 4 | AMGN |
Amgen Inc
This page
|
2,641 | $956,358 | |
| 5 | GRFS |
Grifols SA
|
101,833 | $720,977 | |
| 6 | SNY |
Sanofi
|
12,660 | $540,075 | |
| 7 | NVS |
Novartis AG
|
2,762 | $432,860 | |
| 8 | MRK |
Merck & Co., Inc.
|
2,493 | $320,350 |
All Filings in AMGN
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $956,358 | 2,641 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $459,867 | 1,307 | Shares | Sole | 2026-05-08 | |
| 2025-09-30 | $260,470 | 923 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $659,494 | 2,362 | Shares | Sole | 2025-07-22 | |
| 2025-03-31 | $402,834 | 1,293 | Shares | Sole | 2025-05-08 | |
| 2024-12-31 | $635,440 | 2,438 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $876,411 | 2,720 | Shares | Sole | 2024-11-05 | |
| 2022-06-30 | $1,104,095 | 4,538 | Shares | Sole | 2022-08-09 | |
| 2021-09-30 | $663,680 | 3,121 | Shares | Sole | 2021-11-12 | |
| 2020-03-31 | $397,350 | 1,960 | Shares | Sole | 2020-05-12 | |
| No filing history on record for this holder in this stock. | ||||||